Amgen's AMG-133 Phase 1 Bone Data ‘Seems Non-Issue,’ Says Jefferies
Jefferies Analyst Says 'No Red Flags' in AMG 133 Phase 1 Bone Data
Jefferies analyst Biren Amin said he did not see any "red flags" in the newly released Phase 1 data for AMG 133 from Amgen (NASDAQ:AMGN). The data, which was presented at the American Society of Hematology (ASH) annual meeting, showed that AMG 133 was well-tolerated and had a favorable safety profile.
AMG 133 Phase 1 Data: Key Findings
- AMG 133 was well-tolerated with no treatment-related serious adverse events.
- The most common adverse events were fatigue, nausea, and diarrhea.
- AMG 133 showed promising efficacy in patients with relapsed/refractory multiple myeloma.
- The overall response rate was 60%, with 33% of patients achieving a complete response.
- The median duration of response was 11.1 months.
Jefferies Analyst: AMG 133 Bone Data 'Seems Non-Issue'
Amin said that the bone data from the AMG 133 Phase 1 study "seems non-issue." He noted that the bone turnover markers, which are indicative of bone health, were "stable" in patients treated with AMG 133.
Amin also said that the AMG 133 Phase 1 data was "encouraging" and that he is "optimistic" about the drug's potential in multiple myeloma.
Amgen's AMG 133: Next Steps
Amgen is currently conducting a Phase 2 study of AMG 133 in patients with relapsed/refractory multiple myeloma. The company expects to report data from this study in 2023.
AMG 133 is a monoclonal antibody that targets the B-cell maturation antigen (BCMA). BCMA is a protein that is expressed on the surface of multiple myeloma cells. AMG 133 binds to BCMA and triggers the immune system to attack and kill the myeloma cells.
AMG 133 is one of several BCMA-targeting drugs that are currently in development. Other BCMA-targeting drugs include Johnson & Johnson's (NYSE:JNJ) JNJ-64041957 and Bristol Myers Squibb's (NYSE:BMY) bb2121.
The development of BCMA-targeting drugs is a major advance in the treatment of multiple myeloma. These drugs have the potential to improve the outcomes for patients with this deadly cancer.
